Giuseppe Tosto1, Molly E Zimmerman2, Owen T Carmichael3, Adam M Brickman1. 1. Taub Institute for Research on Alzheimer's Disease and the Aging Brain, Department of Neurology, College of Physicians and Surgeons, Columbia University, New York, New York. 2. The Saul R. Korey Department of Neurology, Albert Einstein College of Medicine, New York, New York. 3. Department of Neurology, University of California-Davis.
Abstract
IMPORTANCE: Although white matter hyperintensities (WMHs) are associated with the risk for Alzheimer disease, it is unknown whether they represent an independent source of impairment or interact with known markers of disease. OBJECTIVE: To examine the degree to which WMHs predict aggressive cognitive decline among individuals with mild cognitive impairment, either independently or by modifying the effects of entorhinal cortex volume (ECV), a marker of Alzheimer disease-related neurodegeneration. DESIGN, SETTING, AND PARTICIPANTS: The Alzheimer's Disease Neuroimaging Initiative is a longitudinal study with 6-month follow-up visits. Three hundred thirty-two participants (mean [SD] age, 74.6 [7.4] years; 118 women) of a total of 374 participants diagnosed as having mild cognitive impairment were included. Participants were excluded if they did not have longitudinal data, apolipoprotein E genotype data, or had evidence of supratentorial infarct. MAIN OUTCOMES AND MEASURES: A decline in Mini-Mental State Examination score of 3 points over 6 months or 6 points over 1 year between consecutive visits was defined as aggressive decline. White matter hyperintensity volume and ECV were entered as predictors in Cox proportional hazards models and Wilcoxon-Breslow tests to examine their impact on this outcome, adjusting for sex, age, education, and apolipoprotein E status. RESULTS:Greater WMH volume at baseline, apolipoprotein E ε4 status, and smaller ECV at baseline were associated with an increased risk for aggressive decline (hazard ratio [HR], 1.23; 95% CI, 1.05-1.43; P = .01 for WMH volume; HR, 1.49; 95% CI, 1.09-2.05; P = .04 for apolipoprotein E ε4 status; HR, 0.66; 95% CI, 0.55-0.79; P < .001 for ECV). White matter hyperintensity volume modified the effect of ECV on aggressive decline risk: individuals with high ECV and low WMH were at particularly low likelihood of decline (χ2 = 15, P = .001). Participants with Mini-Mental State Examination scores that declined by 3 or more points over 6 months or 6 or more points over 12 months were more likely to have converted to Alzheimer disease by the end of the follow-up period (χ2 = 82, P < .001). CONCLUSIONS AND RELEVANCE: White matter hyperintensity burden and ECV predict rapid cognitive decline among individuals with mild cognitive impairment both additively and multiplicatively.
RCT Entities:
IMPORTANCE: Although white matter hyperintensities (WMHs) are associated with the risk for Alzheimer disease, it is unknown whether they represent an independent source of impairment or interact with known markers of disease. OBJECTIVE: To examine the degree to which WMHs predict aggressive cognitive decline among individuals with mild cognitive impairment, either independently or by modifying the effects of entorhinal cortex volume (ECV), a marker of Alzheimer disease-related neurodegeneration. DESIGN, SETTING, AND PARTICIPANTS: The Alzheimer's Disease Neuroimaging Initiative is a longitudinal study with 6-month follow-up visits. Three hundred thirty-two participants (mean [SD] age, 74.6 [7.4] years; 118 women) of a total of 374 participants diagnosed as having mild cognitive impairment were included. Participants were excluded if they did not have longitudinal data, apolipoprotein E genotype data, or had evidence of supratentorial infarct. MAIN OUTCOMES AND MEASURES: A decline in Mini-Mental State Examination score of 3 points over 6 months or 6 points over 1 year between consecutive visits was defined as aggressive decline. White matter hyperintensity volume and ECV were entered as predictors in Cox proportional hazards models and Wilcoxon-Breslow tests to examine their impact on this outcome, adjusting for sex, age, education, and apolipoprotein E status. RESULTS: Greater WMH volume at baseline, apolipoprotein E ε4 status, and smaller ECV at baseline were associated with an increased risk for aggressive decline (hazard ratio [HR], 1.23; 95% CI, 1.05-1.43; P = .01 for WMH volume; HR, 1.49; 95% CI, 1.09-2.05; P = .04 for apolipoprotein E ε4 status; HR, 0.66; 95% CI, 0.55-0.79; P < .001 for ECV). White matter hyperintensity volume modified the effect of ECV on aggressive decline risk: individuals with high ECV and low WMH were at particularly low likelihood of decline (χ2 = 15, P = .001). Participants with Mini-Mental State Examination scores that declined by 3 or more points over 6 months or 6 or more points over 12 months were more likely to have converted to Alzheimer disease by the end of the follow-up period (χ2 = 82, P < .001). CONCLUSIONS AND RELEVANCE: White matter hyperintensity burden and ECV predict rapid cognitive decline among individuals with mild cognitive impairment both additively and multiplicatively.
Authors: Irene B Meier; Jennifer J Manly; Frank A Provenzano; Karmen S Louie; Ben T Wasserman; Erica Y Griffith; Josina T Hector; Elizabeth Allocco; Adam M Brickman Journal: J Int Neuropsychol Soc Date: 2012-03-06 Impact factor: 2.892
Authors: Deepika Bhargava; Myron F Weiner; Linda S Hynan; Ramon Diaz-Arrastia; Anne M Lipton Journal: J Geriatr Psychiatry Neurol Date: 2006-06 Impact factor: 2.680
Authors: Clifford R Jack; David S Knopman; William J Jagust; Leslie M Shaw; Paul S Aisen; Michael W Weiner; Ronald C Petersen; John Q Trojanowski Journal: Lancet Neurol Date: 2010-01 Impact factor: 44.182
Authors: Keith A Josephs; J Eric Ahlskog; Joseph E Parisi; Bradley F Boeve; Brian A Crum; Caterina Giannini; Ronald C Petersen Journal: Arch Neurol Date: 2009-02
Authors: Bradley T Wyman; Danielle J Harvey; Karen Crawford; Matt A Bernstein; Owen Carmichael; Patricia E Cole; Paul K Crane; Charles DeCarli; Nick C Fox; Jeffrey L Gunter; Derek Hill; Ronald J Killiany; Chahin Pachai; Adam J Schwarz; Norbert Schuff; Matthew L Senjem; Joyce Suhy; Paul M Thompson; Michael Weiner; Clifford R Jack Journal: Alzheimers Dement Date: 2012-10-27 Impact factor: 21.566
Authors: Adam M Brickman; Frank A Provenzano; Jordan Muraskin; Jennifer J Manly; Sonja Blum; Zoltan Apa; Yaakov Stern; Truman R Brown; José A Luchsinger; Richard Mayeux Journal: Arch Neurol Date: 2012-12
Authors: Nancy A Kerner; Steven P Roose; Gregory H Pelton; Adam Ciarleglio; Jennifer Scodes; Cody Lentz; Joel R Sneed; D P Devanand Journal: Am J Geriatr Psychiatry Date: 2016-11-17 Impact factor: 4.105
Authors: Takakuni Maki; Yoko Takahashi; Nobukazu Miyamoto; Anna C Liang; Masafumi Ihara; Eng H Lo; Ken Arai Journal: Stem Cell Res Date: 2015-05-09 Impact factor: 2.020
Authors: Michael W Weiner; Dallas P Veitch; Paul S Aisen; Laurel A Beckett; Nigel J Cairns; Robert C Green; Danielle Harvey; Clifford R Jack; William Jagust; John C Morris; Ronald C Petersen; Andrew J Saykin; Leslie M Shaw; Arthur W Toga; John Q Trojanowski Journal: Alzheimers Dement Date: 2017-03-22 Impact factor: 21.566
Authors: Kan Ding; Takashi Tarumi; David C Zhu; Benjamin Y Tseng; Binu P Thomas; Marcel Turner; Justin Repshas; Diana R Kerwin; Kyle B Womack; Hanzhang Lu; C Munro Cullum; Rong Zhang Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Giuseppe Tosto; Molly E Zimmerman; Jamie L Hamilton; Owen T Carmichael; Adam M Brickman Journal: Alzheimers Dement Date: 2015-06-13 Impact factor: 21.566
Authors: Emily R Lindemer; David H Salat; Eric E Smith; Khoa Nguyen; Bruce Fischl; Douglas N Greve Journal: Neurobiol Aging Date: 2015-05-28 Impact factor: 4.673
Authors: Katherine J Bangen; Kelsey R Thomas; Alexandra J Weigand; Danielle L Sanchez; Lisa Delano-Wood; Emily C Edmonds; Owen T Carmichael; Christopher G Schwarz; Adam M Brickman; Mark W Bondi Journal: Neurobiol Aging Date: 2019-11-02 Impact factor: 4.673